UroCompanion
← All topics
OncologyStandardLast updated 29 May 2026

Bladder Cancer

Presentation & Prognosis

At initial diagnosis, ~75–80% present with NMIBC and ~20–25% with MIBC. About 20% of those initially diagnosed with NMIBC progress to MIBC (≥50% of high-risk NMIBC can progress), and patients who progress from NMIBC have a worse prognosis than those who present with MIBC de novo.

MIBC is highly lethal: 5-year overall survival is ~5% untreated vs ~50% treated, and the overall prognosis has not changed in the last 30 years.

Diagnosis and Evaluation

Work-up at a glance: history and physical including exam under anesthesia (EUA) at TURBT; imaging — regional (CT abdomen/pelvis) and distant (chest CT or CXR); labs — CBC, liver function tests, renal function; and TURBT pathology.

  • Exam under anesthesia — performed at TURBT for suspected invasive cancer; informs clinical staging, resectability, and potential NAC benefit. A large/3-D residual mass after TURBT (cT3b), invasion of adjacent structures (cT4a), or fixation (cT4b) implies locally advanced stage.
  • Imaging — goals: feasibility/safety of cystectomy, hydronephrosis, upper-tract disease, local extent, pelvic/retroperitoneal nodes, and visceral/distant metastases. Regional: cross-sectional abdomen/pelvis with IV contrast (if not contraindicated). Metastasis: chest CT or CXR (prior smokers may benefit from chest CT; non-smokers need at least PA and lateral CXR). Bone scan if elevated alkaline phosphatase or bone pain. PET if abnormal chest/abdominal/pelvic imaging needs further evaluation or a suspicious node cannot be biopsied.
  • Laboratory — CBC (anemia, occult infection); liver and renal function (influence choice of urinary diversion given metabolic abnormalities such as acidosis or renal/hepatic insufficiency, and the ability to give chemotherapy). LFTs typically include ALT, AST, ALP, GGT, bilirubin, PT/INR, total protein, albumin.
  • TURBT pathology — informs clinical staging alongside EUA. If variant histology (micropapillary, nested, plasmacytoid, neuroendocrine, sarcomatoid, extensive squamous or glandular differentiation) is suspected or muscle invasion is equivocal, an experienced genitourinary pathologist should review; re-review of cystectomy specimens may identify variants that alter treatment in up to 33% of patients.

Management — Overview

Curative options should be discussed using a multidisciplinary approach, weighing comorbidity and tumour characteristics, and counselling on quality-of-life impacts (continence, sexual function, fertility, bowel dysfunction, metabolic problems). Diversion-specific risks: ileal conduit (external appliance, leakage/stomal complications); continent cutaneous reservoir (lifelong self-catheterization, incontinence, stricture, pouchitis, pouch stones, metabolic derangements); neobladder (incontinence — especially nocturnal — bladder-neck contracture, voiding dysfunction/retention, fistula).

  • Standard treatment of MIBC (cT2–T4a, N0, M0) regardless of histologic subtype is radical cystectomy (RC) + bilateral PLND; timing of NAC and/or radiation varies by histology.
  • If urothelial or neuroendocrine — NAC + RC. Pure neuroendocrine variants are rare but highly aggressive, usually presenting at high stage or with metastasis.
  • If small cell — initial chemotherapy followed by radiation or cystectomy as consolidation (if non-metastatic).
  • If pure non-urothelial (squamous, adenocarcinoma, sarcomatoid) — perioperative chemotherapy is not routinely recommended (generally chemo-resistant).
  • Alternatives: multimodal/trimodal therapy, partial cystectomy + chemotherapy, chemotherapy alone, or radiation alone.

Neoadjuvant & Adjuvant Chemotherapy

Neoadjuvant (NAC):

  • Advantages — better tolerated before surgery; treats micrometastatic disease earlier; downstages bulky/locally advanced tumours (higher likelihood of negative margins); allows assessment of response. NAC does not increase perioperative morbidity.
  • Disadvantages — delays definitive local therapy in non-responders; NAC-related toxicity (VTE, mortality); non-selective nature.
  • Evidence — two large phase III trials showed an OS benefit. SWOG 8710 (Grossman 2003, n=317 cT2–T4aN0M0, MVAC + RC vs RC): pT0 at cystectomy 38% vs 15% (absolute difference 23%); pT0 patients had 80% 5-year survival vs 40% with residual disease; median OS 77 vs 46 months and 5-year OS 57% vs 43%, though survival failed to reach significance (P=.06). BA06 30894 (n=976, neoadjuvant CMV vs cystectomy). 2005 ABC meta-analysis (9 trials, 3,005 patients): NAC improved 5-year OS by 5% and 5-year DFS by 9%, with pT0 rates of 30–40% vs 15%.
  • Regimen — gemcitabine-cisplatin (GC) is frequently used for lower toxicity, despite level 1 evidence only for MVAC and CMV; no completed RCT has compared GC to others (retrospective data suggest no significant difference). Best regimen/duration undefined; most use 3–4 cycles over ~3 months. Dose-dense MVAC (VESPER) did not beat GC for PFS or OS. KEYNOTE-905 (EV + pembrolizumab, n=344 cisplatin-ineligible/declined): 2-year event-free survival 75% vs 39%, 2-year OS 80% vs 63%, pCR 57.1% vs 8.6% (ESMO 2025).
  • Indications — AUA (2020): cisplatin-based NAC should be offered to eligible RC patients. CUA (2019): all eligible cT2–T4a N0 M0 urothelial patients should be encouraged to receive cisplatin-based combination chemotherapy (GC, MVAC, or dd-MVAC) before radical local therapy. If cisplatin-ineligible, proceed to definitive locoregional therapy; carboplatin-based NAC should not be used for resectable cT2–T4aN0 disease.
  • Cisplatin contraindications — AUA: eGFR <60 mL/min, heart failure (NYHA >2), ≥grade 2 hearing loss, ≥grade 2 neuropathy, reduced performance status (ECOG ≥2 or Karnofsky ≤60–70%). CUA absolute (mnemonic "HE2NICE", 6): ≥grade 2 Hearing loss, eGFR ≤50, ≥grade 2 Neuropathy, untreated Infection, Cardiac failure (NYHA >2), ECOG ≥2; relative: eGFR 50–60, recurrent infection with immunosuppression.
  • Timing of RC after NAC — as soon as possible after recovery, ideally within 12 weeks (CUA: 4–6 weeks after NAC, no more than 10); outcomes may be worse if delayed >12 weeks.
  • Cisplatin adverse events (4) — nephrotoxicity, ototoxicity, neurotoxicity, diminished cardiac function; these preclude 30–50% of MIBC patients from safe cisplatin use. No validated predictive factors (including age) for response; eligibility is based on comorbidities and performance status.
  • Histology — NAC is primarily derived from the urothelial setting. A SWOG 8710 secondary analysis found mixed tumours (squamous/glandular differentiation) derived greater benefit from MVAC (HR 0.46) than pure urothelial (HR 0.9). Robust data are lacking for pure non-urothelial histologies; exceptions are pure small cell or neuroendocrine carcinoma, where NAC is the mainstay.

Adjuvant (AC):

  • Patients with pT3–T4 or N+ disease are at high risk after cystectomy and can be offered adjuvant chemotherapy.
  • Advantages — immediate local treatment, avoids delay in chemo-resistant tumours; avoids overtreatment (final pathology selects highest-risk patients).
  • Disadvantages — often difficult/impossible post-cystectomy (surgical deconditioning, declining renal function, complications); 24–52% have renal deterioration making them AC-ineligible, and postoperative complications exclude ~30%.
  • Evidence — no single phase III trial shows an OS benefit vs observation; 2014 meta-analysis (Leow, 9 trials, 945 patients) found a 9% absolute survival benefit at 3 years, though with major methodologic deficiencies. AUA (2020): eligible patients who have not received cisplatin-based NAC and have non-organ-confined (pT3/T4 and/or N+) disease should be offered adjuvant cisplatin-based chemotherapy.
  • NAC vs AC — perioperative chemotherapy confers a survival benefit, with stronger evidence for the neoadjuvant approach.

Neoadjuvant / Adjuvant Immunotherapy

Options (3): nivolumab (adjuvant), pembrolizumab (adjuvant), durvalumab (neoadjuvant/adjuvant).

  • PURE-01 (neoadjuvant pembrolizumab, phase II, n=50): 42% achieved pT0.
  • CheckMate 274 (adjuvant nivolumab 240 mg IV q2 weeks ×1 year vs placebo, n=709 high-risk after radical surgery): disease-free survival 21 vs 11 months (benefit ~10 months); 6-month DFS 75% vs 60% overall (and 74% vs 56% in PD-L1 ≥1%, ~40% of patients); in upper-tract urothelial carcinoma the hazard ratio favoured placebo. Common AEs: pruritus, fatigue, diarrhea; 1% treatment-related deaths.
  • AMBASSADOR (adjuvant pembrolizumab 200 mg IV q3 weeks ×1 year vs observation, n=702): DFS benefit ~5 months (45 vs 40 months); 3-year OS −1.1% (60.8% vs 61.9%).
  • NIAGARA (neoadjuvant/adjuvant durvalumab + GC then RC then adjuvant durvalumab vs GC + RC, n=503 cT2–4a N0–1 M0): pCR 33.8% vs 25.8% (benefit 8%); 24-month event-free survival 67.8% vs 59.8% (benefit 8%).

Radical Cystectomy

(See the Cystectomy procedure page.)

Radical cystectomy + bilateral pelvic lymphadenectomy should be offered to surgically eligible patients with resectable non-metastatic (M0) MIBC; NAC + RC is the standard. Bladder-preserving therapy is associated with decreased survival vs RC, so medically fit patients should be offered cystectomy as standard.

  • Extent — remove the bladder, prostate, and seminal vesicles in males; in females, consider removal of adjacent reproductive organs based on disease and the need for negative margins, but organ-sparing should be considered individually (recent guidelines emphasize organ preservation more). Consider salpingectomy in women not desiring fertility (reduces ovarian-cancer risk).
  • Urethrectomy — indicated for all females not receiving a neobladder, and for males with invasive cancer at the apical urethral margin (assessed by intraoperative frozen section or final pathology); can be done at cystectomy or delayed.
  • Function-preserving — sexual-function-preserving and nerve-sparing offered to organ-confined patients without bladder-neck/urethral/prostate involvement, if oncologic control is not compromised. Prostate/prostate-capsule-sparing in highly select males with negative prostatic urethral and transrectal biopsies. Vaginal-sparing when tumour control is not compromised (absence of trigone/base cancer).
  • Perioperative (ERAS) — optimize performance and nutrition (preoperative carbohydrate loading reduces postoperative insulin resistance); smoking-cessation counselling; consider omitting mechanical bowel prep when only small bowel is used; combined mechanical + pharmacologic VTE prophylaxis (consider starting just before induction; up to 4 weeks post-op); μ-opioid antagonist therapy to accelerate GI recovery (contraindicated if opioids taken ≥1 week pre-op).
  • Urinary diversion — discuss ileal conduit, continent cutaneous, and orthotopic neobladder. Absolute contraindications to continent diversion (6): insufficient bowel length; inability to self-catheterize; inadequate renal function (e.g. eGFR <45); inadequate hepatic function; cancer at the urethral margin and uncorrectable urethral stricture (both specific to orthotopic neobladder). For orthotopic diversion, verify a negative urethral margin (retained-urethra cancer risk 1–17%, mostly within 2 years; risk factors include tumour multiplicity, papillary pattern, CIS, bladder-neck tumour, prostatic urethral involvement and stromal invasion — prostate involvement is the strongest risk factor but does not preclude orthotopic diversion if frozen section is negative; preoperative prostatic urethral biopsies are less reliable than frozen sections).
  • Pelvic lymphadenectomy — bilateral PLND is mandatory at any curative-intent surgery (including unilateral wall involvement, given crossover risk). At minimum remove external iliac, internal iliac, and obturator nodes; a standard template with >12 nodes evaluated facilitates staging. SWOG S1011 (n=592, standard vs extended including common iliac/pre-sciatic/presacral): no DFS or OS difference (5-year DFS 56% extended vs 60% standard), with higher morbidity/mortality in the extended arm. LEA AUO AB 25/02 (n=401, limited vs extended): no significant difference in RFS, CSS, or OS, with more grade ≥3 lymphoceles in the extended group.
  • Prognosis after RC — ~50% ultimately die of disease; most recurrences within 2–3 years. Strongest predictors: pT stage and nodal metastasis; others include margin status, LVI, hydronephrosis, molecular markers, variant histology, BMI, age, sex, surgical expertise, hospital volume, and delay >12 weeks to cystectomy. Systemic recurrence by stage: pT2 20–30%, pT3 40%, pT4 >50%, N+ 70%. Most patients with post-cystectomy recurrence are not cured with current systemic therapy.

Bladder Preservation / Multimodal Therapy

A multidisciplinary discussion is preferred. Successful preservation is multimodal: aggressive TUR + systemic chemotherapy + radiation; single-modality therapy gives inferior results vs RC.

  • Patient selection — for newly diagnosed non-metastatic MIBC patients who wish to retain the bladder, or those with significant comorbidities unfit for cystectomy. Ideal characteristics (4): unifocal tumour, no CIS, no hydronephrosis, and a tumour completely resectable transurethrally. Relative contraindications: large unresectable tumours, multifocal CIS, T3/T4 tumours, hydronephrosis. Outcomes of variant/non-urothelial histology are unknown. Maximal debulking TURBT with assessment of multifocality/CIS (and random biopsies) should be performed.
  • Trimodal therapy includes maximal TURBT, chemotherapy combined with EBRT, and ongoing cystoscopy to evaluate response. Radiosensitizing chemotherapy should be included (radiation + concurrent chemo is superior to radiation alone); cisplatin-based regimens are used (alternatives gemcitabine or 5-FU + MMC for cisplatin-ineligible). Carboplatin is inferior and should not be used as a radiosensitizer unless cisplatin, 5-FU, and gemcitabine are contraindicated. CUA selection (6): unifocal, no CIS, no hydronephrosis, small (<5 cm), good bladder function, motivated patient.
  • Strategies (2) — split-course (induction chemoradiation to ~40 Gy, then restaging; persistent invasive disease → RC, otherwise consolidative chemoradiation to ~64 Gy) and continuous-course (full chemoradiation, then endoscopic restaging at 6 months). Maximal debulking before therapy is critical.
  • Follow-up — offer mid-course evaluation to select non-responders before consolidation; after completion, cystoscopy with biopsy plus regular CT, cystoscopy, and cytology (cystoscopy per high-risk NMIBC schedule; cross-sectional and chest imaging every 6 months for 2 years). Complete responders remain at risk of recurrence and upper-tract tumours.
  • Maximal TURBT / partial cystectomy — medically fit patients who consent to RC should not undergo these as primary curative therapy (associated with increased all-cause mortality). Patients unfit for RC and trimodal therapy may be offered radical maximal TURBT alone (if macroscopically completely resectable and repeat TURBT negative) or partial cystectomy + bilateral PLND + perioperative chemotherapy (cisplatin-eligible) if: accessible location, size <3 cm, no multifocal CIS, no hydronephrosis, adequate bladder function, no residual ≥T1 disease — ~40% will ultimately require cystectomy.
  • Primary chemotherapy alone — limited data (Herr 2008, n=63 who declined cystectomy after complete NAC response): at ≥5 years, 36% died of bladder cancer, 64% alive, 54% with intact bladder. Primary radiotherapy alone should not be offered as curative treatment.
  • Treatment failure — medically fit patients with residual/recurrent muscle-invasive disease after preservation should be offered RC + bilateral PLND (~30% have an invasive recurrence); non-muscle-invasive recurrences may be offered local measures (TURBT + intravesical therapy) or RC.

Summary of MIBC treatment lines: first-line NAC + RC; second-line RC ± AC; third-line multimodal therapy; fourth-line maximal TURBT or partial cystectomy (if criteria met).

Follow-up

  • Imaging — chest and cross-sectional abdomen/pelvis (CT or MRI) every 6–12 months for 2–3 years, then possibly annually (upper-tract urothelial carcinoma after cystectomy occurs in 1–6%); cross-sectional imaging preferably with IV contrast and delayed images; beyond 5 years, base on shared decision-making.
  • Labs/markers — electrolytes, renal function, ± vitamin B12 every 3–6 months for 2–3 years then annually (metabolic derangements and renal decline occur with diversion; assess B12 with >60 cm ileal resection or terminal-ileum use). Routine CBC/LFT for surveillance is not validated, and cytology/urine markers are not supported for upper-tract detection (intestinal cells/atypia lower specificity).
  • Retained urethra — monitor for recurrence; urethral wash cytology may help in higher-risk patients, along with physical exam and discussion of urethral symptoms.
  • Survivorship — discuss coping, support groups/counselling, and healthy lifestyle (smoking cessation, exercise, diet).